MindWalk Holdings Corp. (HYFT)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in CAD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CAD m | 15 | 18 | 19 | 21 | 25 | 25 | 15 | 16 |
| Operating profit | CAD m | -15 | -17 | ||||||
| Net profit | CAD m | -5 | -7 | -17 | -27 | -26 | -30 | -14 | -17 |
| EPS reported | CAD | -0.30 | -0.37 | ||||||
| Operating cashflow per share | CAD | -0.26 | -0.27 | ||||||
| Capex per share | CAD | 0.01 | 0.01 | ||||||
| FCF per share | CAD | -0.27 | -0.28 | ||||||
| Free cash flow | CAD m | -13 | -13 | ||||||
| Net debt | CAD m | -11 | -4 | ||||||
| Book value equity | CAD m | 12 | 7 | ||||||
| Book value per share | CAD | 0.25 | 0.15 | ||||||
| Number of shares | m | 46.38 | 46.81 | ||||||
| DPS (TTM paid) | CAD | 0.00 | 0.00 |
Financial summary
Financials in CAD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 6.39 | 2.92 | ||||||
| P/S LTM | x | 5.27 | 1.25 | ||||||
| P/FCF LTM | x | -5.92 | -1.60 | ||||||
| EV/EBITDA LTM | x | -5.44 | -1.37 | ||||||
| EV/Sales LTM | x | 5.45 | 5.44 | ||||||
| Earnings Yield LTM | % | -19.89% | -15.16% | ||||||
| FCF Yield | % | -16.89% | -62.49% | ||||||
| Quality | |||||||||
| ROE | % | -117.10% | -90.61% | ||||||
| ROIC | % | -89.17% | -89.86% | ||||||
| Operating margin | % | -96.01% | -95.90% | ||||||
| Gross margin | % | +58.80% | +58.79% | ||||||
| FCF/Sales | % | -82.66% | -83.58% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -37.52% | -33.98% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -3.60 | -3.62 | ||||||
| Net Debt/EBITDA | x | 0.59 | 0.56 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +0.61% | +0.50% | ||||||
| Net debt/Equity | x | -0.93 | -0.60 | ||||||
| Gross debt/equity | x | 0.30 | 0.50 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
MindWalk Holdings Corp. functions as an innovative bio-native artificial intelligence firm. Its core mission involves leveraging the synergy of AI, comprehensive multi-omics data, and sophisticated laboratory investigations to accelerate the identification and advancement of biological therapeutics. Utilizing its proprietary LensAI platform and HYFT technology, the company forges partnerships with pharmaceutical and biotechnology enterprises. These collaborations are designed to diminish the inherent risks associated with drug development and to unlock new possibilities for treatments. Founded in 1983, the company adopted its current name, MindWalk Holdings Corp., in September 2025, having previously been known as ImmunoPrecise Antibodies Ltd. Its corporate headquarters are located in Austin, Texas.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
MindWalk Holdings Corp. functions as an innovative bio-native artificial intelligence firm. Its core mission involves leveraging the synergy of AI, comprehensive multi-omics data, and sophisticated laboratory investigations to accelerate the identification and advancement of biological therapeutics. Utilizing its proprietary LensAI platform and HYFT technology, the company forges partnerships with pharmaceutical and biotechnology enterprises. These collaborations are designed to diminish the inherent risks associated with drug development and to unlock new possibilities for treatments. Founded in 1983, the company adopted its current name, MindWalk Holdings Corp., in September 2025, having previously been known as ImmunoPrecise Antibodies Ltd. Its corporate headquarters are located in Austin, Texas.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free